Most Read Articles
6 days ago
Less focus must be given on pretreatment blood pressure (BP) levels, which rarely predict future untreated BP levels or rule out capacity to benefit from BP lowering in high cardiovascular risk patients, according to recent study. Focus must be directed instead on prompt, empirical treatment to maintain lower BP for individuals with high BP or high risk.
16 Nov 2018
Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.
15 Nov 2018
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Audrey Abella, 16 Nov 2018
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.

Age alters relation between cognitive function, intraindividual variability in BP

13 Jan 2018

Intraindividual measurement-to-measurement variation in blood pressure (BP IIV) significantly predicts cognition with advancing age, a study has found.

There was a significant age by BP IIV interaction, according to the investigators.

Among individuals aged >60 years, IIV in systolic (SBP) and diastolic blood pressure (DBP) had an inverse association with Global Composite, Scanning and Tracking and the Similarities test. In addition, IIV in SBP correlated with Verbal Memory and the Mini-Mental State Examination. Furthermore, IIV in DBP was associated with the Visual-Spatial Memory and Organization composite.

No significant associations were observed between BP IIV and cognitive function in individuals aged <60 years.

In one study, researchers found that higher overall variability in both SBP and DBP was associated with poorer cognitive performance in unsuccessfully treated hypertensive individuals (with BP ≥140/90 mm Hg). However, these associations were not evident in those with controlled hypertension. [Hypertension 2014;64:1094-1101]

The present study aimed to assess age by BP IIV (SBP and DBP) interactions vis-à-vis cognitive functioning while considering medication class and polypharmacy, which might also affect BP IIV with advancing age.

A total of 980 community-dwelling individuals from the Maine-Syracuse Longitudinal Study were included in the cross-sectional analyses. Automated BP measures were taken 15 times (five times each in sitting, reclining and standing positions). A thorough neuropsychological test battery was used after the BP assessment to examine cognitive function.

“There is evidence to suggest that BP IIV may be superior to mean BP for predicting cognitive function, taken from both within a single visit and between-visits,” the investigators noted. “BP IIV increases with age in studies of persons middle-aged and older.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Less focus must be given on pretreatment blood pressure (BP) levels, which rarely predict future untreated BP levels or rule out capacity to benefit from BP lowering in high cardiovascular risk patients, according to recent study. Focus must be directed instead on prompt, empirical treatment to maintain lower BP for individuals with high BP or high risk.
16 Nov 2018
Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.
15 Nov 2018
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Audrey Abella, 16 Nov 2018
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.